Skip to main content
    H

    HeartSciences Inc. (HSCS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.08
    -0.04 (-2.12%)

    Market Cap: $10.56M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    HeartSciences Inc. (HSCS) Financials: Revenue, Profit and Cash Flow

    Updated Sep 14, 2026. Financial statements from company filings, amounts in US dollars.

    HeartSciences reported revenue of $4.32K for the fiscal year ended Apr 30, 2026, down 0.7% from the year before. That year, net income was -$9.14M with a net margin of -211666.5%, operating cash flow was -$7.43M and free cash flow was -$7.43M. The quarter ended Jul 31, 2026 had revenue of $2.10K and net income of -$3.17M.

    Revenue and Margins

    Over the 6 years to Apr 2026, revenue fell from $64.18K, a compound annual decline of 36.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Apr 2026$4.32K-0.7%59.1%-194787.4%-211666.5%
    Apr 2025$4.35K-76.6%56.8%-192013.1%-201499.5%
    Apr 2024$18.60K+261.2%67.3%-33902.0%-35511.9%
    Apr 2023$5.15K-64.2%45.7%-118698.3%-123384.3%
    Apr 2022$14.37K-43.9%45.1%-32765.6%-33592.6%
    Apr 2021$25.60K-60.1%-72.9%-10030.2%-9577.3%
    Apr 2020$64.18KN/A-71.8%-5949.0%-5938.0%
    Annual, fiscal years ended Apr 2020 to Apr 2026

    Income Statement

    In the fiscal year ended Apr 2026, the net loss widened from the year before. In the quarter ended Jul 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020
    Revenue$4.32K$4.35K$18.60K$5.15K$14.37K$25.60K$64.18K
    Cost of revenue$1.77K$1.88K$6.08K$2.80K$7.89K$44.28K$110.29K
    Gross profit$2.55K$2.47K$12.52K$2.35K$6.48K-$18.67K-$46.10K
    Research and development$2.84M$4.39M$2.88M$2.46M$3.00M$1.71M$2.04M
    Operating income-$8.41M-$8.35M-$6.31M-$6.11M-$4.71M-$2.57M-$3.82M
    Net income-$9.14M-$8.77M-$6.61M-$6.35M-$4.83M-$2.45M-$3.81M
    EBITDA-$7.76M-$7.85M-$6.05M-$6.02M-$4.52M-$2.29M-$3.74M
    Fiscal years ended Apr 2020 to Apr 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Revenue$2.10K$89.49M$0$2.42K$1.90K$31$0$0$0$0$14.70K$3.90K
    Gross profit$1.34K$29.11M$0$1.41K$1.14K-$81$0$0$0-$9.20K$10.14K$2.38K
    Operating income-$2.94M-$10.55M-$1.93M-$2.07M-$1.87M-$2.03M-$2.37M-$1.99M-$2.08M-$1.88M-$1.53M-$1.57M
    Net income-$3.17M-$6.29M-$1.99M-$2.35M-$2.05M-$1.82M-$2.54M-$2.08M-$2.05M-$1.85M-$1.64M-$1.75M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, short-term debt of $3.62M exceeded cash and equivalents by $1.97M.

    Annual

    Line itemJun 2026Apr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020
    Total assets$5.26M$5.26M$4.22M$9.50M$3.29M$2.09M$1.93M$1.96M
    Current assets$2.58M$2.58M$2.17M$7.35M$2.70M$1.93M$1.64M$1.54M
    Cash and equivalents$1.66M$1.66M$1.10M$5.81M$1.66M$918.26K$723.48K$496.85K
    Total liabilities$5.04M$5.04M$4.02M$2.19M$3.06M$8.15M$3.84M$1.64M
    Short-term debt$3.62M$3.62M$2.55M$500.00K$500.00K$1.63M$487.83K$444.11K
    Long-term debtN/AN/A$0N/A$500.00K$4.44M$2.50M$300.00K
    Shareholder equity$226.06K$226.06K$205.17K$7.32M$230.56K-$6.06M-$1.91M$315.55K
    Fiscal years ended Apr 2020 to Jun 2026

    Quarterly

    Line itemJul 2026Jun 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024
    Total assets$3.74M$5.26M$5.26M$7.55M$6.00M$6.44M$4.22M$5.70M$6.00M$6.44M$9.50M$10.80M
    Total liabilities$5.77M$5.04M$5.04M$4.90M$1.81M$3.30M$4.02M$3.92M$1.81M$3.30M$2.19M$2.17M
    Cash and equivalents$29.91K$1.66M$1.66M$3.40M$1.95M$2.79M$1.10M$2.60M$1.95M$2.79M$5.81M$7.08M
    Shareholder equity-$2.03M$226.06K$226.06K$2.65M$4.18M$3.14M$205.17K$1.79M$4.18M$3.14M$7.32M$8.63M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Apr 2026.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020
    Operating cash flow-$7.43M-$7.41M-$6.07M-$5.77M-$3.64M-$2.45M-$3.84M
    Capital expenditures$3.55K$3.16K$64.45K$18.31K$1.93K$712$11.42K
    Free cash flow-$7.43M-$7.42M-$6.13M-$5.79M-$3.65M-$2.45M-$3.85M
    Investing cash flow-$44.45K-$30.19K-$125.27K-$18.31K-$1.93K-$712$8.17K
    Financing cash flow$8.03M$2.73M$10.34M$6.53M$3.84M$2.68M$1.81M
    Fiscal years ended Apr 2020 to Apr 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Operating cash flow-$1.32M-$1.68M-$1.46M-$2.33M-$1.95M-$1.59M-$1.62M-$2.18M-$2.02M-$1.58M-$2.10M-$988.19K
    Capital expenditures$274.50K$19.03M$9.48M$13.03K$0$7.81K$15.70K$5.84K$833$48.80K$8.79K$1.95K
    Free cash flow-$1.59M-$20.71M-$10.94M-$2.35M-$1.95M-$1.60M-$1.64M-$2.19M-$2.02M-$1.63M-$2.11M-$990.14K
    Last 12 quarters

    Frequently Asked Questions About HSCS

    What is HeartSciences' annual revenue?

    HeartSciences reported revenue of $4.32K for the fiscal year ended Apr 30, 2026.

    How fast is HeartSciences' revenue growing?

    Revenue was down 0.7% for the fiscal year ended Apr 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was -5.7%.

    Is HeartSciences profitable?

    No. HeartSciences reported net income of -$9.14M for the fiscal year ended Apr 30, 2026, with a net margin of -211666.5%.

    How much free cash flow does HSCS generate?

    For the fiscal year ended Apr 30, 2026, operating cash flow of -$7.43M minus capital expenditures of $3.55K produced free cash flow of -$7.43M.

    How much debt does HeartSciences have?

    The balance sheet dated Jun 30, 2026 reported short-term debt of $3.62M and cash and equivalents of $1.66M.